

This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.

Palliative Medicine in Practice

ISSN: 2545-0425

e-ISSN: 2545-1359

Risk of reoperation for anastomotic leakage after anterior resection of rectal cancer after neoadjuvant therapy

Authors: Karolina Osowiecka, Anna Sugajska, Maciej Biernacki, Sergiusz Nawrocki, Monika Rucińska

DOI: 10.5603/PMPI.a2022.0016

Article type: Research paper

Submitted: 2022-05-17

Accepted: 2022-08-08

Published online: 2022-08-30

This article has been peer reviewed and published immediately upon acceptance.

It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited.
The final version may contain major or minor changes.

Original article

DOI: 10.5603/PMPI.a2022.0016

**Karolina Osowiecka¹, Anna Sugajska^{2,3}, Maciej Biernacki^{4,5}, Sergiusz Nawrocki^{2,3},
Monika Rucińska²**

¹Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn, Poland

²Department of Oncology, *Collegium Medicum*, University of Warmia and Mazury in Olsztyn, Poland

³Department of Radiotherapy, Hospital SP ZOZ MSWiA with Warmia and Mazury Oncology Centre in Olsztyn, Poland

⁴Department of Surgery, *Collegium Medicum*, University of Warmia and Mazury in Olsztyn, Poland

⁵Department of General Surgery, Hospital SP ZOZ MSWiA with Warmia and Mazury Oncology Centre in Olsztyn, Poland

Risk of reoperation for anastomotic leakage after anterior resection of rectal cancer after neoadjuvant therapy

Short title: Reoperation for rectal anastomotic leakage

Address for correspondence:

Karolina Osowiecka

Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn, Warszawska 30 St, 10-082 Olsztyn, Poland

e-mail: karolina.osowiecka@uwm.edu.pl

Abstract

Introduction: Rectal cancer patients require a multidisciplinary approach. In the case of locally advanced rectal cancer standard treatment includes neoadjuvant radiotherapy or chemoradiotherapy. Neoadjuvant treatment could cause postoperative complications, but there is no clear evidence of an association between anastomotic leakage and the preoperative treatment of rectal cancer. The aim of this study was to investigate the frequency of anastomotic leakage followed by the need for reoperation and to find predictive factors for reoperation in rectal cancer patients after neoadjuvant therapy.

Patients and methods: One hundred and ten consecutive patients (median age: 65 years) with locally advanced operable rectal cancer, Clinical Stages II and III, were treated with neoadjuvant radiotherapy or chemoradiotherapy (72% were treated with short radiotherapy only, 3% with short radiotherapy and subsequent chemotherapy, 25% with long radiotherapy plus concomitant chemotherapy) and then anterior rectal resection with total mesorectal excision in the Regional Oncological Centre between January 2014 and December 2016.

Results: The reoperation for anastomotic leakage was done in 17% of patients, 8 days (median) after primary surgery. In multivariate analysis reoperation for anastomotic leakage was significantly frequent in older patients ($p = 0.03$) and in upper tumors ($p = 0.04$).

Conclusions: Almost one fifth of rectum cancer patients after preoperative radio- or chemoradiotherapy in our series required reoperation due to anastomotic leakage. The study findings are limited by its small sample size and retrospective character.

Key words: anastomotic leakage, neoadjuvant treatment, rectum cancer, reoperation, mesorectal excision

Introduction

The incidence of rectal cancer in Poland accounts for 4.1% of all reported cancers in men and 2.7% in women. In 2017, the number of newly diagnosed cases of rectum cancer in Poland was over 3500 [1]. The majority of cases occur among men between 50 and 80 years old and in women over 70 years old. For patients diagnosed and treated in the years 2000–2007 in

Poland, the five-year overall survival is 37%; in the European population, the average survival rate is 48% [2].

Rectal cancer patients require a multidisciplinary approach. Standards of rectal cancer treatment have been introduced over the last two decades [3–5]. Surgery is still the primary rectal cancer treatment. The total mesorectal excision (TME) technique has significantly reduced the risk of local recurrence in locally advanced rectal cancer — from about 25% to 10% [6–9]. However, in the case of locally advanced rectal cancer, standard treatment includes neoadjuvant radiotherapy and chemoradiotherapy [6, 10]. Preoperative radiotherapy has resulted in a decreasing risk of local recurrence by up to 4–5%, without a significant overall survival benefit [9, 11]. The indication for preoperative radiotherapy in locally advanced rectal cancer is cT3 or cN1–2 [5]. In relation to postoperative radiotherapy, preoperative treatment significantly reduces toxicity and prevents local recurrence [12]. There are two main patterns of preoperative treatment for operable rectal cancer [13]. Preoperative radiotherapy alone may be administered in a short cycle delivered over 5 days, to a total dose of 25 Gy (in 5 fractions), followed by surgery within a week. The second option is neoadjuvant chemoradiotherapy (concomitant or sequential) followed by surgery within 4–6 weeks [14]. However, neoadjuvant treatment may cause some tissue disturbances such as oedema, blood supply disorders, fibrosis, and even necrosis. This could cause some postoperative complications, such as anastomotic leakage, and a need for reoperation.

Anastomotic leakage is the most important postoperative complication after rectal cancer resection. This complication prolongs hospitalization and could cause an increase in the risk of postoperative mortality to 6–22% [15–17]. Anastomotic leakage led to a significant increase in 90-day mortality, especially in the elderly [18]. It appears that anastomotic leakage could be associated with local recurrence, the need for a permanent stoma, and worse prognosis [17, 19, 20]. Wang et al. [21] in meta-analysis showed that anastomotic leakage was associated with a significantly higher rate of local recurrence and decreased overall survival and cancer-specific survival without impacting distant metastases. There is no clear evidence of an association between anastomotic leakage and neoadjuvant treatment of rectal cancer in the available literature. The aim of this retrospective study was to determine the incidence of anastomotic leakage followed by the need for reoperation and to find the predictive factors of a reoperation in rectal cancer patients treated with neoadjuvant radiotherapy or chemoradiotherapy.

Patients and methods

A retrospective analysis was carried out on 110 consecutive patients with locally advanced operable rectal cancer treated with neoadjuvant radiotherapy or chemoradiotherapy and then anterior rectal resection with total mesorectal excision — complete removal of the rectum, together with the surrounding mesorectum lymphovascular fatty tissue (mesorectum) — in the Regional Oncological Centre between January 2014 and December 2016. The list of patients was generated from the hospital's electronic database. The clinical data was collected from the medical documentation of each patient — partly from the electronic database and partly from paper records (histopathological reports and protocols of surgery) by investigators (surgeon and oncologists). The variables that could be associated with rectal reoperation and time to reoperation for anastomotic leakage (sex, age, tumor localization, pT stage, pN stage, preoperative stoma, extent of resection, circumferential resection margin, and administered radiotherapy or radio-chemotherapy) were analyzed. The missing data was not included in the analysis of individual factors. An ethical approval for this study was not required due to retrospective analysis of the data.

Statistics

Descriptive statistics were used to characterize group. Uni- and multivariable predictors of reoperation were estimated through logistic regression analysis. Univariate variables with $p < 0.25$ were included in the multivariable model. The time to reoperation was measured from the date of surgery to the date of reoperation for anastomotic leakage. A p -value < 0.05 was considered statistically significant. The analysis was performed using TIBCO Software Inc. (2017). Statistica (data analysis software system), version 13. <http://statistica.io>.

Results

One hundred and ten consecutive patients (71 males and 39 females, age: 42–89 years, median age: 65 years) with histologically confirmed locally advanced rectal adenocarcinoma treated in Hospital Oncology Centre between January 2014 and December 2016 were analyzed. All patients received neoadjuvant treatment: 79 patients (72%) were treated with short radiotherapy only (25 Gy in 5 fractions), 4 patients (3%) with short radiotherapy (25 Gy in 5 fractions) with subsequent chemotherapy, and 27 patients (25%) with long radiotherapy to a total dose 50.4 Gy in 28 fractions, with concomitant chemotherapy. Clinical stages of cancer were II and III (cT3-4N0M0 or cT1-4N1-2M0) according to the TNM/AJCC 2002

classification [22]. About 50% of patients had tumor localization ≥ 6 cm from the anus. In the case of 11 patients (10%), it was necessary to use stoma before oncological treatment.

Pathological confirmation of rectum cancer after operation was done in all subjects, but in the case of 7 patients (6%) it was carcinoma in situ. Most tumors were classified as pT3 (64%). In the case of 63 patients (57%), there were no metastases in lymph nodes. Primary complete radical resection of the tumor was done in 87 patients (79%). In some cases, it was possible to expand the operation margin. Finally, operation R0 was performed in 96 patients (87%) (Table 1).

The reoperation for anastomotic leakage was done in 19 out of 110 patients (17%). The time interval between primary surgery and reoperation ranged from 2 to 30 days (median: 8 days). Reoperation for anastomotic leakage was more frequent in males, older patients, those with a tumor localized ≥ 6 cm from the anus, and those with pN (+), but the differences were not statistically significant. In univariate analysis only four factors met inclusion criteria to multivariate regression model ($p < 0.25$). In multivariate analysis, reoperation was significantly frequent in older patients — age ≤ 65 vs. > 65 years (OR: 3.80; 95% CI: 1.13–12.73, $p = 0.03$) — and in patients with upper tumor — tumor localization < 6 vs. ≥ 6 cm (OR: 3.42; 95% CI: 1.05–11.08, $p = 0.04$) (Table 2, Fig. 1).

Discussion

In the literature, the authors reported 3–17.0% clinical anastomotic leakage after rectal cancer resection [20, 23–26]. In our series, the reoperation for anastomotic leakage was done in 17% of rectum cancer patients after neoadjuvant treatment, 8 days (median) after primer operation. Anastomotic leakage typically becomes clinically apparent in 5–8 days post operation [15, 23, 27]. In some studies, the risk of anastomotic leakage was higher in patients receiving pre-operative radiotherapy [16, 28, 29]. Eriksen et al. [16] observed anastomotic leakage in 23.7% of patients after neoadjuvant radiotherapy and in 11.3% of patients without radiotherapy. Sparreboom et al. [30] based on data from the Dutch ColoRectal Audit showed that the incidence of anastomotic leakage was significantly higher in patients who underwent surgery in short interval (< 4 days) after short-term radiotherapy alone (10.1% vs. 7.2%). A study by Kerr et al. [31] reported that shortening the interval between the completion of neoadjuvant chemoradiotherapy and surgery resulted in an increased percentage of anastomotic leakage. However, a meta-analysis found no effect of neoadjuvant therapy for rectal cancer on the

incidence of postoperative anastomotic leakage [32]. In addition, the interval to surgery after preoperative radiotherapy (short- or long-course, with or without chemotherapy) were not associated with an increased rate of postoperative anastomotic leakage [32]. Our patients included only those with preoperative treatment, so we could not compare patients treated preoperatively or not. We did not observe any differences in the incidence of anastomotic leakage depending on the type of neoadjuvant treatment.

Clinical stage is one factor correlated with anastomotic leakage after rectal cancer removal [16, 33]. Patients with more advanced tumors classified as T4 had a 2.4 times higher risk of anastomotic leakage compared to \leq T3 [16]. There was no association between T stage and anastomotic leakage in our series, but in only 8 patients (7%), the tumor was classified as T4. Instead, we found a correlation between stage N and the rate of anastomotic leakage in our study. Patients with lymph node invasion significantly frequently underwent reoperation due to anastomotic leakage.

Some authors mentioned that the independent risk factor for anastomotic leakage is a low anastomotic level: 4–6 cm or less from the anal verge [16, 24, 33–35]. In our analysis, reoperation was more often done in cases localized higher than 6 cm. This finding may be accidental and related to a relatively small subgroups of patients. However, Akiyoshi et al. [36] showed, also in a small group comprising 87 rectal cancer patients after laparoscopic TME, that the independent predictive factor for overall postoperative morbidity and anastomotic leakage was a longer tumor distance from the anal verge.

In a multivariate analysis, the risk of anastomotic leakage was significantly higher in males [16, 23, 30, 33, 37]. Our results are similar. Reoperation for anastomotic leakage was more frequent in males, but the differences were not statistically significant, possibly due to small subgroups. One of the probable reasons for this is the narrow male pelvis, which makes visualization during operation more difficult. Patient age is a controversial factor — in one analysis, anastomotic leakage appeared more often in younger patients [37]; in another, it was more common in older patients [23]. In our study, in multivariate analysis, reoperation was significantly frequent in patients aged $>$ 65 years. This could be related to beta error due to a small number of patients in subgroups.

Hoshino et al. [33] used the data of 936 patients that had been prospectively collected by the Japanese Society for Colon and Rectal Cancer and identified the most relevant combination of predictors for anastomotic leakage: male sex, low serum albumin level, proximity of the tumor to the anal verge, large tumor size, and simultaneous resection of other organs. On this

basis, they created a nomogram for precise prediction of anastomotic leakage after low anterior resection for rectal cancer. The authors concluded that preoperative therapy was considered to be a potential risk factor for anastomotic leakage, but neoadjuvant treatment was not identified in this study to be related to more frequent anastomotic leakage because of the small number of the patients who received preoperative therapies [33].

Conclusions

The reoperation due to anastomotic leakage after preoperative radio- or chemoradiotherapy in our series concerned almost one-fifth of rectum cancer patients. In our study, an older age, a high location of the tumor was related to anastomotic leakage and the need for reoperation. However, the study was limited by its small sample size and retrospective design. Anastomotic leakage is associated with a local recurrence and has a negative impact on the overall survival of rectal cancer patients. Therefore, special attention should be paid to all possible factors increasing the risk of anastomotic leakage, and the resulting findings should be employed by all attempts to decrease the incidence of anastomotic leakage.

Declaration of conflict of interests

Authors declare no conflict of interest.

Funding

This research received no external funding.

References

1. Krajowy Rejestr Nowotworów; Nowotwory złośliwe odbytnicy (C19-20). <http://onkologia.org.pl/nowotwory-zlosliwe-odbytnicy-c19-20/> (1.12.2016).
2. Eurocare 5 Survival Analysis. <http://www.eurocare.it/Database/tabid/77/Default.aspx> (1.12.2016).
3. Glimelius B, Tiret E, Cervantes A, et al. ESMO Guidelines Working Group. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2013; 24 Suppl 6: vi81–vi88, doi: 10.1093/annonc/mdt240, indexed in Pubmed: 24078665.

4. Glynne-Jones R, Wyrwicz L, Tiret E, et al. ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2018; 29(Suppl 4): iv263, doi: 10.1093/annonc/mdy161, indexed in Pubmed: 29741565.
5. NCCN clinical practice guidelines in oncology. NCCN Guidelines: Rectal cancer. Version: 2.2020. https://www.nccn.org/guidelines/category_1 (1.02.2020).
6. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med.* 2001; 345(9): 638–646, doi: 10.1056/NEJMoa010580, indexed in Pubmed: 11547717.
7. Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. *J Clin Oncol.* 2005; 23(24): 5644–5650, doi: 10.1200/JCO.2005.08.144, indexed in Pubmed: 16110023.
8. Peeters KC, Marijnen CAM, Nagtegaal ID, et al. Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. *Ann Surg.* 2007; 246(5): 693–701, doi: 10.1097/01.sla.0000257358.56863.ce, indexed in Pubmed: 17968156.
9. Gijn Wv, Marijnen C, Nagtegaal I, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol.* 2011; 12(6): 575–582, doi: 10.1016/s1470-2045(11)70097-3.
10. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. *Lancet.* 2001; 358(9290): 1291–1304, doi: 10.1016/s0140-6736(01)06409-1, indexed in Pubmed: 1684209.
11. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. *Radiother Oncol.* 2004; 72(1): 15–24, doi: 10.1016/j.radonc.2003.12.006, indexed in Pubmed: 15236870.
12. Sauer R, Becker H, Hohenberger W, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med.* 2004; 351(17): 1731–1740, doi: 10.1056/NEJMoa040694, indexed in Pubmed: 15496622.
13. Klenova A, Georgiev R, Kurtev P, et al. Short versus conventional preoperative radiotherapy of rectal cancer: indications. *JBUON.* 2007; 12 (2): 227–232. PMID. ; 17600877.
14. Tural D, Ozturk M, Selcukbiricik F. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer. *J BUON.* 2013; 18(2): 385–390, indexed in Pubmed: 23818350.
15. Daams F, Luyer M, Lange JF. Colorectal anastomotic leakage: aspects of prevention, detection and treatment. *World J Gastroenterol.* 2013; 19(15): 2293–2297, doi: 10.3748/wjg.v19.i15.2293, indexed in Pubmed: 23613621.
16. Eriksen MT, Wibe A, Norstein J, et al. Anastomotic leakage following routine mesorectal excision for rectal cancer in a national cohort of patients. *Colorectal Dis.* 2005; 7(1): 51–57, doi: 10.1111/j.1463-1318.2004.00700.x, indexed in Pubmed: 15606585.

17. den Dulk M, Marijnen CAM, Collette L, et al. Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery. *Br J Surg.* 2009; 96(9): 1066–1075, doi: 10.1002/bjs.6694, indexed in Pubmed: 19672927.
18. Boström P, Haapamäki MM, Rutegård J, et al. Population-based cohort study of the impact on postoperative mortality of anastomotic leakage after anterior resection for rectal cancer. *BJS Open.* 2019; 3(1): 106–111, doi: 10.1002/bjs5.50106, indexed in Pubmed: 30734021.
19. Branagan G, Finnis D. Prognosis after anastomotic leakage in colorectal surgery. *Dis Colon Rectum.* 2005; 48(5): 1021–1026, doi: 10.1007/s10350-004-0869-4, indexed in Pubmed: 15789125.
20. Holmgren K, Kverneng Hultberg D, Haapamäki MM, et al. High stoma prevalence and stoma reversal complications following anterior resection for rectal cancer: a population-based multicentre study. *Colorectal Dis.* 2017; 19(12): 1067–1075, doi: 10.1111/codi.13771, indexed in Pubmed: 28612478.
21. Wang S, Liu J, Wang S, et al. Adverse effects of anastomotic leakage on local recurrence and survival after curative anterior resection for rectal cancer: a systematic review and meta-analysis. *World J Surg.* 2017; 41(1): 277–284, doi: 10.1007/s00268-016-3761-1, indexed in Pubmed: 27743072.
22. Greene FL, Page DL, Fleming ID. Colon and rectum. In: American Joint Committee on Cancer: *AJCC Cancer Staging Manual.* 6th ed. Springer, New York, New York 2002.
23. Kingham TP, Pachter HL. Colonic anastomotic leak: risk factors, diagnosis, and treatment. *J Am Coll Surg.* 2009; 208(2): 269–278, doi: 10.1016/j.jamcollsurg.2008.10.015, indexed in Pubmed: 19228539.
24. Yeh CY, Changchien CR, Wang JY, et al. Pelvic drainage and other risk factors for leakage after elective anterior resection in rectal cancer patients: a prospective study of 978 patients. *Ann Surg.* 2005; 241(1): 9–13, doi: 10.1097/01.sla.0000150067.99651.6a, indexed in Pubmed: 15621985.
25. Eckmann C, Kujath P, Schiedeck THK, et al. Anastomotic leakage following low anterior resection: results of a standardized diagnostic and therapeutic approach. *Int J Colorectal Dis.* 2004; 19(2): 128–133, doi: 10.1007/s00384-003-0498-8, indexed in Pubmed: 14752675.
26. Cong ZJ, Hu LH, Bian ZQ, et al. Systematic review of anastomotic leakage rate according to an international grading system following anterior resection for rectal cancer. *PLoS One.* 2013; 8(9): e75519, doi: 10.1371/journal.pone.0075519, indexed in Pubmed: 24086552.
27. Hyman N, Manchester TL, Osler T, et al. Anastomotic leaks after intestinal anastomosis: it's later than you think. *Ann Surg.* 2007; 245(2): 254–258, doi: 10.1097/01.sla.0000225083.27182.85, indexed in Pubmed: 17245179.
28. Mirnezami A, Mirnezami R, Chandrakumaran K, et al. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. *Ann Surg.* 2011; 253(5): 890–899, doi: 10.1097/SLA.0b013e3182128929, indexed in Pubmed: 21394013.
29. Dekker JW, Liefers GJ, de Mol van Otterloo JCA, et al. Predicting the risk of anastomotic leakage in left-sided colorectal surgery using a colon leakage score. *J Surg Res.* 2011; 166(1): e27–e34, doi: 10.1016/j.jss.2010.11.004, indexed in Pubmed: 21195424.

30. Sparreboom CL, Wu Z, Lingsma HF, et al. Dutch ColoRectal Audit Group. Anastomotic leakage and interval between preoperative short-course radiotherapy and operation for rectal cancer. *J Am Coll Surg.* 2018; 227(2): 223–231, doi: 10.1016/j.jamcollsurg.2018.03.034, indexed in Pubmed: 29609024.
31. Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. *Br J Surg.* 2008; 95(12): 1534–1540, doi: 10.1002/bjs.6377, indexed in Pubmed: 18942057.
32. Hu MH, Huang RK, Zhao RS, et al. Does neoadjuvant therapy increase the incidence of anastomotic leakage after anterior resection for mid and low rectal cancer? A systematic review and meta-analysis. *Colorectal Dis.* 2017; 19(1): 16–26, doi: 10.1111/codi.13424, indexed in Pubmed: 27321374.
33. Hoshino N, Hida K, Sakai Y, et al. Nomogram for predicting anastomotic leakage after low anterior resection for rectal cancer. *Int J Colorectal Dis.* 2018; 33(4): 411–418, doi: 10.1007/s00384-018-2970-5, indexed in Pubmed: 29411120.
34. Marusch F, Koch A, Schmidt U, et al. Early postoperative results of surgery for rectal carcinoma as a function of the distance of the tumor from the anal verge: results of a multicenter prospective evaluation. *Langenbecks Arch Surg.* 2002; 387(2): 94–100, doi: 10.1007/s00423-002-0298-6, indexed in Pubmed: 12111262.
35. Rutkowski A, Olesiński T, Zając L, et al. The risk of anastomotic leakage after anterior resection: retrospective analysis of 501 rectal cancer patients operated without protective stoma. *Minerva Chir.* 2017; 72(6): 491–498, doi: 10.23736/S0026-4733.17.07411-9, indexed in Pubmed: 28621509.
36. Akiyoshi T, Kuroyanagi H, Oya M, et al. Factors affecting the difficulty of laparoscopic total mesorectal excision with double stapling technique anastomosis for low rectal cancer. *Surgery.* 2009; 146(3): 483–489, doi: 10.1016/j.surg.2009.03.030, indexed in Pubmed: 19715805.
37. Parthasarathy M, Greensmith M, Bowers D, et al. Risk factors for anastomotic leakage after colorectal resection: a retrospective analysis of 17 518 patients. *Colorectal Dis.* 2017; 19(3): 288–298, doi: 10.1111/codi.13476, indexed in Pubmed: 27474844.

Table 1. Patient and treatment characteristics

	N	%
No. of patients	110	100
Sex		
Males	71	65
Females	39	35
Age [years]	median: 65; range: 42–89	
≤ 65	56	51
> 65	54	49
Tumor localization [cm]	median: 5; range: 0–15	
< 6	57	52
≥ 6	53	48
pT status		
in situ	7	6
T1	0	0
T2	25	23
T3	70	64
T4	8	7
pN status		
N0	63	57
N1	29	27
N2	18	16
Preoperative stoma		
Yes	11	10
No	99	90
Primary resection margin		
Negative	87	79
Positive	23	21
Radial	9	8
Proximal	1	1
Distal	8	7
Distal-radial	2	2
Unknown	3	3
Finally extent of resection		
R0	96	87

	R1	10	9
	R2	1	1
	No data	3	3
<hr/>			
Neoadjuvant treatment			
	Short radiotherapy	79	72
	Short radiotherapy plus chemotherapy	4	3
	Long radiochemotherapy	27	25
<hr/>			

Table 2. Uni- and multivariate analysis of distribution of reoperation for anastomotic leakage

Variable	Univariate analysis			Multivariate analysis			
		OR	(95% CI)	p-value	OR	(95% CI)	p-value
Sex	Females	1.00	Reference	0.16	1.00	Reference	0.10
	Males	2.34	(0.72–7.64)		2.96	(0.81–10.79)	
Age	≤ 65	1.00	Reference	0.18	1.00	Reference	0.03
	> 65	2.00	(0.72–5.54)		3.80	(1.13–12.73)	
Tumor localization [cm]	< 6	1.00	Reference	0.06	1.00	Reference	0.04
	≥ 6	2.76	(0.97–7.91)		3.42	(1.05–11.08)	
pT status	In situ	1.00	Reference	0.63	–	–	–
	T2	0.63	(0.09–4.22)				
	T3–4	0.46	(0.08–2.62)				
pN status	N (–)	1.00	Reference	0.34	–	–	–
	N (+)	1.62	(0.60–4.38)				
Preoperative stoma	Yes	1.00	Reference	0.93	–	–	–
	No	0.93	(0.19–4.71)				
Primary circumferential resection margin	Positive	1.00	Reference	0.17	1.00	Reference	0.12
	Negative	4.28	(0.53–34.37)		5.51	(0.64–47.53)	
Finally extent of resection	R0	1.00	Reference	1.00	–	–	–
	R 1–2	0.0	(0.0–0.0)				
Chemotherapy	Yes	1.00	Reference	0.84	–	–	–
	No	1.12	(0.37–3.43)				
Radiotherapy	Long	1.00	Reference	0.70	–	–	–
	Short	1.27	(0.38–4.21)				

OR — odds ratio; CI – confidence interval




Figure 1. The ratio of rectal cancer patients reoperated to non-reoperated for anastomotic leakage depending on tumor localization and patients' age ($p < 0.05$)